Intra-Arterial Thrombolysis After SUCCESSful Angiographic Recanalization in Acute Large Vessel Occlusion Stroke of the Anterior Circulation: the IA-SUCCESS Multicenter, Randomized Clinical Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Stroke is a leading cause of disability and mortality worldwide. Despite the clinical benefit of mechanical thrombectomy, 1 out of 2 patients treated are functionally independent at 90 days. Achieving the best possible angiographic reperfusion is a key determinant of clinical outcome in acute ischemic stroke patients with anterior circulation large vessel occlusion. Mechanical thrombectomy is standard treatment for large vessel occlusion stroke patients within 24. In the setting of successful (eTICI ≥2b), adjunct intra-arterial thrombolysis may be a promising therapeutic option allowing recanalization of distal arterial occlusions (not accessible to mechanical devices) and improvement of upstream brain reperfusion by targeting microvascular obstruction. The IA-SUCCESS randomized trial aims to assess the clinical and safety of adjunct intra-arterial thrombolysis vs. no adjunct intra-arterial thrombolysis after successful angiographic reperfusion in patients with acute anterior circulation large vessel occlusion stroke.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Pre-stroke mRS 0-2

• Acute ischemic stroke with anterior circulation large vessel occlusion defined as intracranial internal carotid artery, M1, or M2 occlusion proven on CT or MRI

• NIHSS score ≥ 5 at admission

• Acute reperfusion strategy started within 24h after stroke onset according to the international guidelines

• DWI-ASPECTS ≥ 2 (MRI) or CT-ASPECTS ≥ 3

• Delay from imaging to puncture within 3 hours for transferred patients

• eTICI 2b-2c-3 after intravenous thrombolysis alone, bridging therapy, or mechanical thrombectomy alone and confirmed by catheter angiogram

• Person affiliated to or beneficiary of a social security plan

Locations
Other Locations
France
CHRU Nancy
RECRUITING
Nancy
Contact Information
Primary
Benjamin GORY, MD, PHD
b.gory@chru-nancy.fr
+33 3 83 85 15 01
Backup
Guillaume TURC, MD, PhD
G.TURC@ghu-paris.fr
+33 1 45 65 86 65
Time Frame
Start Date: 2025-06-01
Estimated Completion Date: 2029-07-01
Participants
Target number of participants: 626
Treatments
Experimental: Adjunct intra-arterial thrombolysis
Adjunct intra-arterial thrombolysis with Alteplase 0.225mg/kg after intravenous thrombolysis intravenous thrombolysis alone, bridging therapy, or mechanical thrombectomy alone.
No_intervention: No intra-arterial thrombolysis
Control group: no intra-arterial thrombolysis after intravenous thrombolysis alone, bridging therapy, or mechanical thrombectomy alone (according to standard of care).
Related Therapeutic Areas
Sponsors
Leads: Central Hospital, Nancy, France

This content was sourced from clinicaltrials.gov